BVI Expands IOL Capacity with New State of the Art Facility in Belgium

Posted on

WALTHAM, Mass. — July 18th, 2023 (GLOBE NEWSWIRE) — BVI, one of the fastest growing surgical ophthalmic businesses in the world, is proud to announce the opening of its new, state of the art facility in Liège, Belgium.  This results in a sizeable increase in BVI’s intraocular lens (IOL) business capacity, unlocking new growth opportunities and reinforcing the company’s environmental, social, and governance (ESG) leadership. Leer más

BVI launches FINEVISION HP, a novel hydrophobic trifocal IOL based on the FINE optical technology platform, in Japan.

Posted on
  • FINEVISION HP is the first patented diffractive trifocal IOL and is one of the flagship products in BVI’s IOL portfolio; FINE Trifocal technology is utilized across the company’s entire range of presbyopia-correcting IOLs.
  • The Japan launch follows two key FINEVISION HP 2023 milestones: One million FINEVISION IOL implants sold worldwide and the recent completion of the FINEVISION HP IDE clinical study patient enrollment in the US.
  • BVI expects to introduce several IOL models over the next few years in Japan, demonstrating BVI’s commitment to ophthalmic surgeons and their patients in Japan.

WALTHAM, Mass., June 19th, 2023 (GLOBE NEWSWIRE) BVI, one of the fastest growing surgical ophthalmic businesses in the world, is thrilled to announce the official launch of FINEVISION HP in Japan. The FINEVISION HP hydrophobic and glistening free trifocal IOL represents a significant breakthrough in trifocal technology as the first trifocal platform to offer cataract patients high quality vision across all distances.  Leer más

BVI Announces Certification for its Intraocular Lens Portfolio under the European Medical Device Regulation

Posted on

WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- BVI, a diversified global ophthalmic device company, today announced certification for its intraocular lens (IOL) portfolio under the European Medical Device Regulation (MDR, (EU) 2017/745) from its Notified Body, the British Standards Institution (BSI)¹. The new regulatory criteria came into effect in May 2021, replacing the prior Medical Device Directive (MDD). Leer más

BVI acquires Benz Research & Development, strengthening end to end IOL design, production and sales capabilities

Posted on
  • Benz R&D is the leading technologically advanced independent supplier of performance materials and manufacturing technology to the IOL industry
  • BVI’s vertical integration will accelerate manufacturing capacity and geographic sales expansion, and the IOL material capabilities of BVI’s world leading PhysIOL® lens platform

Waltham, MA – October 15, 2020  Leer más

Gold | Professional Sales Tool, 2020

Posted on

BVI and Merge 

CustomEyes Configurator

With 1,400 products sold in markets around the world, BVI was struggling with a convoluted sales process. Sales reps were frustrated with antiquated procedures, including a physical catalog to find and enter SKUs into a spreadsheet, emailing orders to support teams for verification and building the sample pack.  Continue reading the article today! Leer más

BVI expands Malosa single-use instrument range in the US

Posted on
  •  BVI broadens its widely popular range of Malosa® single-use ophthalmic instruments to
    span cataract, oculoplastic, corneal refractive procedures and other office-based
    procedures.
  • Malosa single-use instruments help surgeons focus on precision, reduce cross
    contaminations, and increase operating room efficiency.

Waltham, MA – September 8, 2020 – BVI, the fastest growing diversified company in
ophthalmology, today announced the extension of its Malosa®
range of single-use ophthalmic
instruments in the US. The US Malosa portfolio will now include specialty instruments for use in
corneal refractive surgery, complementing the existing single-use product range for cataract,
oculoplastic and office-based procedures, such as LASIK, PRK and SMILE®. Leer más